李學鋒,殷亞妮,李富軍,盧放根,鄒益友,吳小平
1.中南大學湘雅二醫(yī)院消化科,湖南 長沙 410011;2.中南大學湘雅醫(yī)院消化科
克羅恩病與腸結核患者出院后隨訪分析
李學鋒1,殷亞妮1,李富軍2,盧放根1,鄒益友2,吳小平1
1.中南大學湘雅二醫(yī)院消化科,湖南 長沙 410011;2.中南大學湘雅醫(yī)院消化科
目的 探討克羅恩病(Crohn’s disease,CD)和腸結核(intestinal tuberculosis,ITB)患者出院后的病情變化和預后。方法 選取住院診斷為CD和ITB患者各50例,電話隨訪得到患者出院后進一步的診治和疾病預后等具體資料,并進行總結分析。結果 腸結核隨訪成功34例,平均隨訪(28.77±10.53)個月,最后確診31例;CD隨訪成功32例,平均隨訪(29.56±14.90)個月,最后確診32例。腸結核患者服藥依從性好,平均服藥(13.77±7.06)個月,已愈29例,復發(fā)2例。CD患者服藥以5-氨基水楊酸為主,服藥依從性欠佳,平均服藥(15.31 ±11.12)個月,緩解穩(wěn)定9 例(28.1%),好轉16 例(50.0%),病情加重7 例(21.9%),出院后復發(fā)23例(71.9%),出院后手術治療3例(9.4%)。住院期間13例CD手術患者中,緩解穩(wěn)定6例,好轉5例,病情加重2例,短期內總體效果優(yōu)于非手術治療患者。結論 腸結核預后好、復發(fā)低,應指導按療程服藥,加強隨診。CD預后不佳、復發(fā)率高,應加強出院后隨訪,提高服藥依從性。手術治療對部分患者短期緩解穩(wěn)定有益,這可能與CD臨床表型有關。
克羅恩病;腸結核;隨訪;預后
腸結核(ITB)雖是病因明確的腸道炎癥,但很難獲得特異性的病理學診斷依據,目前仍以臨床綜合診斷為主;克羅恩病(CD)是一種病因不明的腸道非特異性炎癥,其診斷需臨床表現、內鏡特征、放射學及病理學特點綜合診斷[1-3]。CD和ITB都需要長期服藥、隨診及用藥指導,CD和ITB在住院的短期時間內很難觀察到藥物的療效和驗證診斷的正確性,有時短期內的治療有效和癥狀改善甚至有一定迷惑性而引起誤診[4-6]。因此,開展CD和ITB出院后的隨訪既有利于進一步明確疾病診斷、療效和轉歸,又有助于總結CD和ITB的特點及鑒別要點。
1.1 研究對象 從我們前期研究建立CD和ITB數據庫(其中CD 130例、ITB 122例)中選取出院12個月以上的CD和ITB患者各50例作為研究對象[7-8]。
1.2 研究方法 設計CD和ITB電話隨訪調查表,通過電話隨訪得到患者出院后進一步的診治及預后等資料。
1.3 統(tǒng)計學處理 數據采用SPSS 14.0統(tǒng)計學軟件處理,先進行統(tǒng)計描述,對各數據結果進行構成比統(tǒng)計,CD手術病例和非手術病例隨訪結果比較采用t檢驗和卡方檢驗,以P<0.05為差異有統(tǒng)計學意義。
2.1 腸結核隨訪結果 50例ITB電話隨訪成功34例,隨訪率68.0%。31例診斷為腸結核,3例誤診:1例出院后抗結核治療3個月出現腸穿孔于08年9月手術治療,病理學診斷:1.腸結核?2.克羅恩病?手術后未再服藥,病情穩(wěn)定無復發(fā)。1例出院后反復腹痛、便血,診斷為克羅恩病,按CD治療有效,服藥依從性差,癥狀反復。1例出院后抗結核治療4個月病情加重,最后確診為多發(fā)性骨髓瘤,化療6個療程,病情穩(wěn)定。31例腸結核患者電話隨訪情況見表1。

表1 31例腸結核患者電話隨訪內容及結果Tab 1 Follow-up contents andResultsof 31 ITB patients
2.2 CD患者隨訪情況
2.2.1 CD患者隨訪內容及結果:50例CD電話隨訪成功32例,隨訪率64.0%。32例出院后仍診斷為CD。32例CD患者電話隨訪情況(見表2)。
2.2.2 CD手術患者隨訪結果:在隨訪的32例CD患者中,有13例在住院時手術治療。出院后出現不同的預后結果見表3。
2.2.3 13例住院手術患者與19例住院非手術患者隨訪結果比較:手術患者的服藥依從性和隨診依從性均明顯低于非手術患者(P<0.01;P<0.05),而手術組緩解穩(wěn)定的患者比非手術組比率有增高趨勢,復發(fā)率低于非手術組見表4。

表2 32例CD患者電話隨訪內容及結果Tab 2 Follow-up contents andResultsof 32 CD patients
CD近年來在結核病流行的發(fā)展中國家不斷增多。腸結核是可治愈的疾病,而CD至今仍無根治藥物和方法,容易出現狹窄和穿孔等并發(fā)癥[9-10]。因此,對臨床表現、內鏡及病理學特點相似、均主要依靠臨床診斷的CD和腸結核進行出院后隨訪追蹤,有利于進一步明確臨床診斷的正確性、了解疾病的療效和預后,同時又可總結CD和腸結核在長期治療過程中的演變及鑒別特點,這也是臨床醫(yī)學的需要。
本研究發(fā)現,在31例最后確診為腸結核中,29例已治愈,2例明顯好轉。說明腸結核是可治愈疾病,同時醫(yī)囑、指導用藥清楚,患者服藥依從性好也是保障療效的基礎。在隨訪中發(fā)現的問題是:(1)患者復診或門診復查的依從性很差,多為間隔3~5個月復查1次;(2)服藥療程最短6個月、最長31個月,服藥時間超過24個月的有4例,4例還在服藥的患者中,2例是療程不足,2例療程已超過24個月,隨診時醫(yī)生已告之治愈,偶有輕微腹痛或腹部不適又自服抗結核藥物,療程不規(guī)范。療程不足容易復發(fā),療程過長易發(fā)生結核菌耐藥和毒副作用,應引起重視。我國對肺結核診治有嚴格的管理制度即:全國實施現代結核病控制策略落實肺結核患者的歸口管理和督導治療管理(DOTS管理)[11],對肺外結核也應如此。

表3 13例CD手術患者出院后隨訪結果Tab 3 Follow-up contents andResultsof 13 cases of postoperative patients with CD

表4 13例手術患者與19例非手術患者隨訪結果比較Tab 4 Comparison of follow up between opreation group and non operation group
本研究發(fā)現在平均隨訪的30個月里,CD病情緩解穩(wěn)定9例、好轉16例、惡化7例,說明CD是一種預后不佳的難治性疾病。由于病因不清、發(fā)病機制不明,34.4%的患者訴說出院時醫(yī)生醫(yī)囑不清楚,59.4%的患者服藥依從性差,這都可能是病情反復復發(fā)的主要原因。總結32例隨訪資料發(fā)現:(1)出院后90.6%的患者以5-ASA作為維持用藥,聯合使用激素或免疫抑制劑者5例。無生物制劑使用者,抗CD藥物使用比較單一,按病情階段對藥物進行升降級處理病例不多;(2)患者服藥依從性差,CD不能根治且治療效果不佳、治療藥物貴可能是服藥依從性差的主要原因;(3)復診、隨診依從性差,65.6%的患者不重視隨診;(4)CD復發(fā)率高,71.9%(23例)的患者出院后復發(fā)1次或1次以上。
本研究一個有趣的發(fā)現是13例住院手術患者隨訪中,有6例出院后無1次復發(fā),并且均已停藥,停藥9~55個月仍保持緩解穩(wěn)定,其中3例手術治療患者,手術后未服任何抗CD藥物而穩(wěn)定無1次復發(fā);4例手術后堅持或間斷服藥,病情好轉;2例手術治療出院后病情惡化,其中1例進行了二次手術。手術治療組緩解穩(wěn)定率明顯高于非手術組,且復發(fā)率低。Sachar等[12]對34例CD手術患者的隨訪發(fā)現:12例因行B2狹窄亞型的手術患者在3年內均無復發(fā),22例因行B3穿透亞型的手術患者12例(54.5%)在3年內復發(fā)。本研究緩解穩(wěn)定者多以梗阻或腫塊致腸腔狹窄原因手術,與Sachar等的研究結果相符合。手術雖然對CD患者來說是“雙刃劍”,但只要嚴格掌握手術指證,同時結合患者的臨床表型選擇手術時機和方式,對患者病情的緩解穩(wěn)定可能有幫助。總之,在CD的治療過程中,應強調治療的難度,重視病情觀察和區(qū)分不同的疾病轉歸,更強調個體化的治療原則[13]。
腸結核是常見的消化道疾病,醫(yī)生容易趨向性診斷腸結核或診斷性抗結核治療。34例住院診斷為腸結核出院后31例最后診斷為腸結核,診斷正確性為91.2%,可見在我國CD患者日益增多的情況下,臨床醫(yī)生應適度調整診斷思維模式,同時出院后隨訪、加強復診是對CD和腸結核這類以臨床診斷為主而難以鑒別疾病的有用方法。
[1] Carter MJ,Lobo AJ,Travis SP.Guidelines for the management of inflammatory bowel disease in adults [J].Gut,2004,53 Suppl 5:v1-v16.
[2] Lennard-Jones JE.Classification of inflammatory bowel disease[J].Scand J Gastroenterol,1989,170:2-6.
[3] IBD group,Chinese consensus on standard management of inflammatory bowel diseases(2007,Jian)[J].Chin J Dig,2007,27(8):545-550.
中華醫(yī)學會消化病學分會炎癥性腸病組.對我國炎癥性腸病診斷治療規(guī)范的共識意見(2000年,濟南)[J].中華消化雜志,2007,27(8):545-550.
[4] Enkai S,Miyakawa T,Kondou S,et al.A case of disseminated BCG infection found during treatment of an infant with Crohn’s disease[J].Kekkaku,2009,84(8):597-603.
[5] Ertekin V,Selimoglu MA,Ok?u N,et al.Intestinal tuberculosis mimicking Crohn’s disease[J].J Emerg Med,2007,33(4):421-423.
[6] Chang YY,Ouyang Q,Hu RW.An analysis of misdiagnosed Crohn’s disease in China[J].Chin J Dig Endosc,2005,22(6):372-375.
常玉英,歐陽欽,胡仁偉.我國克羅恩病的漏診誤診情況分析[J].中華消化內鏡雜志,2005,22(6):372-375.
[7] Li XF,Zou YY,Zhou MH,et al.Clinical and endoscopic diagnosis in the Differentiation of Crohn’s disease from Intestinal tuberculosis[J].Chin J Dig,2010,30(1):11-14.
李學鋒,鄒益友,周明歡,等.克羅恩病與腸結核臨床及內鏡特征的鑒別分析[J].中華消化雜志,2010,30(1):11-14.
[8] Li X,Liu X,Ouyang C,et al.Predictors of clinical and endoscopic findings in differentiating Crohn’s disease from intestinal tuberculosis[J].Dig Dis Sci,2011,56(1):188-196.
[9] Louis E,Collard A,Oger AF,et al.Behaviour of Crohn's disease according to the Vienna classification:changing pattern over the course of the disease[J].Gut,2001,49(6):777-782.
[10] Chow DK,Leong RW,Lai LH,et al.Changes in Crohn’s Disease Phenotype over Time in the Chinese Population:Validation of the Montreal Classification System [J].Inflamm Bowel Dis,2008,14(4):536-541.
[11] Department of disease control of the ministry of health.Work guideline of planning and implementation of TB control in China[S].2008.
衛(wèi)生部疾病控制司.中國結核病防治規(guī)劃實施工作指南[S].2008.
[12] Sachar DB,Lemmer E,Ibrahim C,et al.Recuurence patterns after first resection for structuring or penetrating Crohn’s disease[J].Inflamm Bowel Dis,2009,15(7):1071-1075.
[13] Ouyang Q.Standardixed diagnosis and treatment for inflammatory bowel disease[J].Chin J Intern Med,2008,47(1):1-2.
歐陽欽.重視炎癥性腸病的規(guī)范化診斷與治療[J].中華內科雜志,2008,47(1):1-2.
Study on the follow up of Crohn’s disease and intestinal tuberculosis
LI Xuefeng1,YIN Yani1,LI Fujun2,LU Fanggen1,ZOU Yiyou2,WU Xiaoping1
1.Department of Gastroenterology,the Xiangya Second Hospital,Central South University,Changsha 410011;2.Department of Gastroenterology,the Xiangya Hospital,Central South University,China
ObjectiveTo study the diagnosis,treatment and prognosis of the post-discharged patients diagnosed Crohn’s disease and intestinal tuberculosis in clinic.Methods50 cases of CD and 50 cases of ITB cases were selected.The detailed material such as the further treatment and its prognosis were obtained through telephone follow-up.Results34 ITB cases were followed up and 31 cases were definitely diagnosed.The average followed up duration was(28.77 ±10.53)months.32 CD cases were followed up and 32 cases were definitely diagnosed.The average followed up duration was(29.56 ±14.90)months.ITB patients had a good drug compliance.The average drug-administration duration was(13.77 ±7.06)months.29 cases were cured and 2 cases relapsed.But the compliance was bad.CD patients took 5-ASA mostly and drug administration compliance was poor.The average drug-administration duration was(15.31 ±11.12)months.9 cases(28.1%)were in steady remission status.16 cases were mend(50.0%).7 cases were deteriorated(21.9%).23 cases(71.9%)were relapsed after discharged.And 3 cases(9.4%)were operated after discharged.In 13 CD surgical patients,6 cases were in steady remission status.5 cases were mend.2 cases were deteriorated.The general effect was better than non-operative patients.ConclusionThe prognosis of intestinal tuberculosis was good and had a low recurrence.Patients should be instructed to take medicine course of treatment and follow up on time.The prognosis of CD was bad and had a high recurrence,patients should be advised to have regular follow-up after discharged to improve drug compliance.Surgical treatment is beneficial for some patients,because it can obtain a short-time remission and stability,which may be associated with clinical phenotypes of the patients.
Crohn’s disease;Intestinal tuberculosis;Follow up;Prognosis
R574.62
A
1006-5709(2012)08-0767-04
2011-12-31
10.3969/j.issn.1006-5709.2012.08.024
李學鋒,博士,副主任醫(yī)師。E-mail:longs9877@yahoo.com.cn
盧放根,教授,博士生導師。E-mail:lufanggenyao@163.com.